ABVC - ABVC BioPharma, Inc.
ABVC BioPharma, Inc. , a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
As of May 15, 2026: spot at $1.07, ATM IV 17.5%, net GEX $0.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $15.5M
- Beta
- 0.42
- 52-Week Range
- 0.88-5.48
- CEO
- Uttam Yashwant Patil
- Employees
- 16
- IPO Date
- Nov 10, 2004
- Exchange
- NASDAQ
What ABVC Looks Like to Options Traders Today
IV rank of 1.8% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($0) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes.
What This Page Covers
The ABVC overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked ABVC overview questions
- What is ABVC?
- ABVC is the ticker symbol for ABVC BioPharma, Inc., a listed security. ABVC BioPharma, Inc. , a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. Listed on NASDAQ. ABVC is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the ABVC options snapshot look like today?
- As of May 15, 2026, the ABVC options snapshot shows spot at $1.07, ATM IV 17.5%, IV rank 1.8%, net GEX $0, expected move 5.02%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are ABVC's key statistics?
- ABVC BioPharma, Inc. (ABVC) carries a market capitalization of $15.5M, beta of 0.42 relative to the broader market, 52-week range of 0.88-5.48. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does ABVC belong to?
- ABVC BioPharma, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ABVC's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the ABVC data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).